IDH1 and acute myeloid leukemia: In contrast to TET2, IDH1/2 present few mutations that can be commonly observed in AML and that induce the formation of 2-hydroxy-glutarate, a metabolite that inhibits TET2, leading to similar effects to TET2 mutations [15].